[Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer]

Area of Science:

• Oncology
• Pulmonology

Background:

• Lung cancer is the leading cause of cancer mortality in Germany.
• Metastasis is a common characteristic of lung cancer.
• Systemic therapy is the primary treatment for most non-small cell lung cancer (NSCLC) patients.

Purpose of the Study:

• To summarize current treatment strategies for metastatic non-small cell lung cancer (NSCLC).
• To provide updated therapy recommendations for physicians treating NSCLC.

Main Methods:

• Review of recent advancements in systemic therapy for NSCLC.
• Inclusion of molecular, histologic, and clinical factors in treatment decision-making.
• Consideration of evolving supportive and bronchoscopic therapies.

Main Results:

• Systemic treatment for NSCLC has significantly advanced with new agents like tyrosine kinase inhibitors and immune modulators.
• Identifying targetable oncogenic alterations is crucial for effective treatment.
• Clinical decision-making requires integrating molecular, histologic, and clinical data.

Conclusions:

• Updated therapy recommendations are essential due to rapid advancements in NSCLC treatment.
• Personalized medicine approaches are increasingly important for managing metastatic NSCLC.
• Comprehensive management includes systemic therapy and supportive care, such as bronchoscopic interventions.